Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Orlucent, Inc
With
NHS Lanarkshire
NHS Tayside
NHS Greater Glasgow and Clyde
University Hospitals, Leicester
University of Dundee
The purpose of this study is to establish the clinical utility of the MDS while continuing to evaluate the safety and performance of the MDS in patients with skin lesions who are referred to secondary care clinics for evaluation, whose lesions (moles) are suspicious for melanoma.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Lesion has one or more of the ABCDE features and is recommended for excision.
2. Lesion has at least 1 cm of skin around it that is accessible to the MDS.
3. Patient is at least 18 years old.
4. Patient is capable of giving written informed consent.
5. Lesion is scheduled for primary excision.
You may not be if
1. Lesion is less than one centimetre from the eyes.
2. Lesion is on the palms of the hands or soles of the feet.
3. Lesion is mucosal.
4. Lesion is ulcerated.
5. Patient is pregnant.
6. Low patient study procedure compliance.
7. Patient who is mentally or physically unable to comply with all aspects of the study.
8. Patient is undergoing chemotherapy.
9. Patient has known sensitivity to fluorescent dyes.
10. Ink marking on or adjacent to lesion.
11. Lesions larger than 20mm or too large to allow imaging.
Clareo Health | Investigating the Clinical Utility of the MDS
